On February 15, 2018, the SEC filed an emergency action against Acorda Therapeutics, Inc. (NASDAQ:ACOR) for violating the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  The SEC's complaint alleges that Acorda violated Section 17(a) of the Securities Act and Section 10(b) of the Exchange Act and Rule 10b-5 thereunder and Section 17(a) of the Securities Act.  The complaint alleges that Acorda violated the antifraud provisions of Sections 206(1) and 206(2) of the Investment Advisers Act of 1940 ("Advisers Act") and Section 10(b) of Exchange Act Rule 10b-5 thereunder.  Without admitting or denying the allegations in the complaint, Acorda has agreed to the entry of a final judgment that permanently enjoins it from violating Section 17(a) of the Securities Act, Section 10(b) of the Exchange Act, Rule 10b-5 thereunder, and Rule 10b-5 thereunder. The settlement is subject to court approval.  The SEC's investigation, which is continuing, is being conducted by Jennifer Yee, Phil Nadeau, and Laura Chico of the SEC's Market Abuse Unit, with assistance from John Rymas of the Market Abuse Unit's Analysis and Detection Center. The litigation will be led by Ms. Yee and Mr. Rymas. The SEC appreciates the assistance of the U.S. Attorney's Office for the District of New York, the Federal Bureau of Investigation, and the Financial Industry Regulatory Authority.